Serbian Journal of Anesthesia and Intensive Therapy (Jan 2019)

Novel role of spironolactone in the therapy of resistant hypertension: Spironolactone and resistant hypertension

  • Dragojević-Simić Viktorija,
  • Rančić Nemanja,
  • Dekanski Dragana,
  • Gligorić Danka,
  • Ljubojević Nadežda

Journal volume & issue
Vol. 41, no. 7-8
pp. 157 – 166

Abstract

Read online

Spironolactone is a competitive nonselective mineralocorticoid receptor blocker with high affinity for aldosterone; therefore, it is widely used as a diuretic and antihypertensive. Because of these properties it is used in the treatment of edema in congestive heart failure, liver cirrhosis with ascites and edema, nephrotic syndrome, malignant ascites, severe heart failure and primary hyperaldosteronism. Spironolactone is recommended for the treatment of resistant hypertension. Narrative review aims to present the pharmacodynamic and pharmacokinetic profile of spironolactone, and describe its position in the treatment of resistant hypertension.

Keywords